Efficacy and Safety of Treatment With an Anti-M2e Monoclonal Antibody in Experimental Human Influenza

Abstract

These data indicate that TCN-032 may provide immediate immunity and therapeutic benefit in influenza A infection, with no apparent emergence of resistant virus. TCN-032 was safe with no evidence of immune exacerbation based on serum cytokine expression. Clinicaltrials.gov registry number. NCT01719874.